References
- Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–1657.
- Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–S9.
- Ardizzone S, Puttini PS, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253–S259.
- Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–1122.
- Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol. 2011;17:2702–2707.
- Danese S, Semeraro S, Papa A, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11:7227–7236.
- Cesarini M, Angelucci E, Foglietta T, et al. Guillain-Barré syndrome after treatment with human anti-tumor necrosis factor α (adalimumab) in a Crohn's disease patient: case report and literature review. J Crohns Colitis. 2011;5:619–622.
- Morís G. Inflammatory bowel disease: an increased risk factor for neurologic complications. World J Gastroenterol. 2014;20:1228–1237.
- Benavente L, Morís G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol. 2011;18:138–143.
- Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin Rheumatol. 2009;28:S53–S55.
- Sejvar JJ, Kohl KS, Gidudu J, Brighton Collaboration GBS Working Group, et al. Guillain-Barré syndrome and fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612.
- Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366:2294–2304.
- Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol. 2010;257:1421–1431.
- Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006;54:1429–1434.
- Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:281–292.
- TNF neutralization in MS: results of randomized, placebo-controlled multicenter study. The Lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology. 1999;53:457–465.
- Casella G, Tontini GE, Bassotti G, et al. Neurological disorders and inflammatory bowel diseases. World J Gastroenterol. 2014;20:8764–8782.
- Oliveira GR, Teles BC, Brasil EF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population-based cohort of IBD patients. Inflamm Bowel Dis. 2008;14:389–395.
- Gondim FA, Brannagan TH, Sander HW, et al. Peripheral neuropathy in patients with inflammatory bowel disease. Brain. 2005;128:867–879.
- Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129:819–826.
- Alvarez-Lario B, Prieto-Tejedo R, Colazo-Burlato M, et al. Severe Guillain–Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol. 2013;32:1407–1412.
- Tsang RS, Valdivieso-Garcia A. Pathogenesis of Guillain-Barre syndrome. Expert Rev Anti Infect Ther. 2003;1:597–608.
- Ding T, Ledingham J, Luqmani R; Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee; BHPR, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology. 2010;49:2217–2219.
- Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010;69:1691–1693.